IDEX (IEX) 10-K Summary — Year Ended Dec 31, 2023
IDEX Corporation reported slightly higher annual revenue and strong operating income, as pricing and productivity gains offset sharp volume declines from customer inventory destocking. The company generated substantial operating cash flow despite lower sales volumes, particularly in its Health & Science Technologies segment.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
IDEX Corporation reported slightly higher annual revenue and strong operating income, as pricing and productivity gains offset sharp volume declines from customer inventory destocking. The company generated substantial operating cash flow despite lower sales volumes, particularly in its Health & Science Technologies segment.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$3.3B
Revenue reported for the fiscal year.
Operating income
$732.5M
Income from operations reported for the year.
Net income
$596.1M
Net income reported for the year.
Operating cash flow
$716.7M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $2.8B | n/a |
| Dec 31, 2022 | $3.2B | +15.1% |
| Dec 31, 2023 | $3.3B | +2.9% |
Business overview
IDEX is an applied solutions provider that manufactures fluid and metering technologies, health and science technologies, and fire, safety, and other diversified products built to customer specifications. Its products are sold in niche markets across many industries worldwide. The company's performance is influenced by industrial activity, economic conditions, and currency exchange rates.
Financial performance
Revenue grew modestly from the prior year, with strong price/cost management and operational productivity offsetting volume declines caused by customer inventory destocking, especially in the Health & Science Technologies segment. Operating income and net income remained solid, and operating cash flow was robust. The trend shows revenue growth slowing compared to the previous year.
Material risks
The filing includes a section on risk factors, but the supplied data does not contain the specific risk descriptions. Therefore, no material risks can be identified from the provided context.
Liquidity and capital
Operating cash flow exceeded net income, indicating strong cash generation. No specific liquidity or capital allocation themes were elaborated in the supplied filing excerpts.
What to watch
Monitor the pace of customer inventory destocking and any recovery in order volumes, particularly in the Health & Science Technologies segment.